About: Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease
Creator	Pegan, Scott Hogan, Robert Tripp, Ralph Freitas, Brendan Crich, David Durie, Ian Longo, Jaron Miller, Holden Murray, Jackelyn
source	Medline; PMC
abstract	[Image: see text] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19, is a novel human betacoronavirus that is rapidly spreading worldwide. The outbreak currently includes over 3.7 million cases and 260,000 fatalities. As a betacoronavirus, SARS-CoV-2 encodes for a papain-like protease (PLpro) that is likely responsible for cleavage of the coronavirus (CoV) viral polypeptide. The PLpro is also responsible for suppression of host innate immune responses by virtue of its ability to reverse host ubiquitination and ISGylation events. Here, the biochemical activity of SARS-CoV-2 PLpro against ubiquitin (Ub) and interferon-stimulated gene product 15 (ISG15) substrates is evaluated, revealing that the protease has a marked reduction in its ability to process K48 linked Ub substrates compared to its counterpart in SARS-CoV. Additionally, its substrate activity more closely mirrors that of the PLpro from the Middle East respiratory syndrome coronavirus and prefers ISG15s from certain species including humans. Additionally, naphthalene based PLpro inhibitors are shown to be effective at halting SARS-CoV-2 PLpro activity as well as SARS-CoV-2 replication.
has issue date	2020-05-19(xsd:dateTime)
bibo:doi	10.1021/acsinfecdis.0c00168
bibo:pmid	32428392
has license	no-cc
sha1sum (hex)	b9bb3232d781b15b31e77fe0f826fcde3ce4f649
schema:url	https://doi.org/10.1021/acsinfecdis.0c00168
resource representing a document's title	Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease
has PubMed Central identifier	PMC7274171
has PubMed identifier	32428392
schema:publication	ACS Infect Dis
resource representing a document's body	covid:b9bb3232d781b15b31e77fe0f826fcde3ce4f649#body_text
is schema:about of	named entity 'cases' named entity 'host' named entity 'SARS-CoV' named entity 'protease' named entity 'SARS-CoV-2' named entity 'BIOCHEMICAL ACTIVITY' named entity 'FATALITIES' named entity 'INCLUDING' named entity 'SUPPRESSION' named entity 'VIRTUE' named entity 'REVEALING' named entity 'UBIQUITIN' named entity 'EFFECTIVE' named entity 'UBIQUITINATION' named entity 'LIKELY' named entity 'IMMUNE RESPONSES' named entity 'RESPONSIBLE' named entity 'IS A' named entity 'ABILITY TO' named entity 'SUBSTRATE' named entity 'POLYPEPTIDE' covid:arg/b9bb3232d781b15b31e77fe0f826fcde3ce4f649 named entity 'process' named entity 'substrates' named entity 'effective' named entity 'linked' named entity 'SARS-CoV-2' named entity 'reduction' named entity 'prefers' named entity 'mirrors' named entity 'betacoronavirus' named entity 'humans' named entity 'encodes' named entity 'PLpro' named entity 'betacoronavirus' named entity 'SARS-CoV-2' named entity 'innate immune responses' named entity 'PLpro' named entity 'interferon-stimulated gene' named entity 'ubiquitin' named entity 'PLpro' named entity 'biochemical' named entity 'SARS-CoV-2' named entity 'Papain' named entity 'Deubiquitinase' named entity 'product' named entity '7.9' named entity 'DTT' named entity 'proteases' named entity 'ubiquitin' named entity 'PLpro' named entity 'imidazole' named entity 'PLpro' named entity 'multiplicity of infection' named entity 'SARS-CoV-2' named entity 'agarose' named entity 'E. coli' named entity 'PLpro' named entity 'IPTG' named entity '7.5' named entity 'SARS-CoV-2' named entity 'PLpro' named entity 'antiviral' named entity 'imidazole' named entity 'NaCl' named entity 'PLpro' named entity 'PLpro' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'mice' named entity 'UIM' named entity 'Wuhan' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software